For the Inventor, By the Inventor

Enter assignee name

Exton, PA, United States of America

Morphotek, Inc.

USPTO Granted Patents = 65

% Expired Patents = 18.5

CIPO Patents = 15

EPO Patents = 16

Forward Citations = 301

Loading Chart...

Loading Chart...

27 inventors (with patents filed for the assignee):

Nicholas C Nicolaides (54 out of 88 patents)

Luigi Grasso (53 out of 72 patents)

Philip M Sass (51 out of 58 patents)

4. Wolfgang Ebel (13 out of 13 patents)

5. Eric Routhier (11 out of 11 patents)

6. Bert Vogelstein (9 out of 245 patents)

7. Kenneth W Kinzler (8 out of 222 patents)

8. Abdellah Sentissi (8 out of 8 patents)

9. Douglas B Jacoby (8 out of 12 patents)

10. Yuhong Zhou (6 out of 16 patents)

11. Tao Sai (5 out of 15 patents)

12. Marc Berger (5 out of 6 patents)

13. Jian Li (5 out of 5 patents)

14. Qimin Chao (5 out of 5 patents)

15. Kamala Kesavan (4 out of 4 patents)

Core Competencies:

Monoclonal Antibodies

Chlorotoxin Polypeptides

GM-CSF Peptides

Tumor Antigens

Prognosis Methods

Metastatic Tumors

Immune Effector Activity

Anti-GD2 Antibodies

Endosialin Binding

Hybridomas

Angiogenesis Inhibition

Antimicrobial Agents

65 patents: Sort by Forward Citations

1. 10183975 - Chlorotoxin polypeptides and conjugates and uses thereof (2019-01-22),

2. 10023632 - Antigenic GM-CSF peptides and antibodies to GM-CSF (2018-07-17),

3. 9915660 - Methods for determining prognosis of colorectal cancer (2018-03-13),

4. 9868780 - [object Object] (2018-01-16),

5. 9771429 - TEM-1 diagnostic antibodies (2017-09-26),

6. 9650440 - Monoclonal antibodies that specifically block biological activity of a tumor antigen (2017-05-16),

7. 9637526 - Chlorotoxin polypeptides and conjugates and uses thereof (2017-05-02),

8. 9624297 - Monoclonal antibodies that specifically block biological activity of a tumor antigen (2017-04-18),

9. 9603952 - Treatment of metastatic tumors (2017-03-28),

10. 9522195 - Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells (2016-12-20),

11. 9512223 - Methods for treatment of gastric cancer (2016-12-06),

12. 9505842 - Methods for inhibiting the binding of endosialin to ligands (2016-11-29),

13. 9422367 - Antigenic GM-CSF peptides and antibodies to GM-CSF (2016-08-23),

14. 9359428 - [object Object] (2016-06-07),

15. 9234015 - Chlorotoxin polypeptides and conjugates and uses thereof (2016-01-12),

MorphoTek, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative antibody-based therapeutics. With a focus on cancer treatments, Morphotek utilizes its proprietary antibody discovery technologies to deliver targeted therapies that have the potential to improve patient outcomes. Through ongoing research and partnerships, the company continues to advance novel antibody candidates and contribute to the progress of medical science.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Morphotek, Inc.

65 Patents

#6 in Exton, PA

#211 in Pennsylvania

#5,600 in US

#11,305 in the World

Exton, PA, United States of America

Morphotek, Inc.

Forward Citations = 301

27 inventors:

Nicholas C Nicolaides (54 out of 88 patents)

Luigi Grasso (53 out of 72 patents)

Philip M Sass (51 out of 58 patents)

4. Wolfgang Ebel (13 out of 13 patents)

5. Eric Routhier (11 out of 11 patents)

Please report any incorrect information to [email protected]

Loading…